How do step-therapy mandates affect patient access to advanced UC treatments?

Most U.S. commercial payers require documented failure on mesalamine bowel therapy and at least one conventional immunosuppressant before authorizing biologics for colitis. This creates 6–12-month treatment delays that can worsen mucosal damage and increase colectomy risk [20]. Read More

What role do treat-to-target protocols play in drug selection within the Ulcerative Colitis Market?

Treat-to-target protocols mandate escalation based on objective endoscopic and histologic endpoints rather than symptom scores alone. This approach favors agents with proven mucosal healing data, accelerating adoption of IL-23 inhibitors for IBD remission induction [13]. Read More

How does cold-chain complexity influence biologic distribution in emerging markets?

Monoclonal antibodies require 2–8°C storage throughout the supply chain, which limits penetration in regions lacking reliable refrigeration infrastructure. This gap advantages oral JAK inhibitors and S1P modulators for colon inflammation treatment in rural Asia-Pacific and African settings [11]. Read More

What patent expiry timelines will reshape the Ulcerative Colitis Market competitive dynamics?

Vedolizumab faces patent expiration around 2032–2033, while tofacitinib's composition-of-matter patent expired in 2023. Biosimilar entry post-expiry typically compresses originator pricing by 40–60% within three years [6]. Read More

How are real-world evidence registries influencing payer decisions for inflammatory bowel disease therapy?

National registries like ENEIDA and the UK IBD Registry provide long-term effectiveness and safety data that payers increasingly require for formulary listing. Agents with strong registry-confirmed persistence rates gain preferential reimbursement positioning [19]. Read More

What surgical intervention rates persist despite advances in medical therapy?

Approximately 10–15% of UC patients still require colectomy within ten years of diagnosis despite biologic availability. This residual surgical burden represents an unmet need driving investment in combination IBD remission induction strategies [2]. Read More

How do companion diagnostic developments affect the Ulcerative Colitis Market outlook?

Emerging proteomic and transcriptomic assays can predict biologic response with increasing accuracy, enabling personalized drug selection. Adoption of these tools could reduce treatment cycling costs by 20–30% and improve mesalamine bowel therapy escalation decisions [15]. Read More

Ulcerative Colitis Market (2025 - 2035)

ID: MRFR/Pharma/1737-HCR 85 Pages Vikita Thakur Last Updated: September 15, 2026

溃疡性结肠炎市场研究报告信息按类型（溃疡性直肠炎、直肠乙状结肠炎、左侧结肠炎、全结肠炎或普遍性结肠炎和暴发性结肠炎）、按药物（5-氨基水杨酸盐、类固醇、嘌呤类似物、免疫调节剂和生物制剂）和按地区（北美、欧洲、亚太地区和世界其他地区）划分 - 到 2034 年的市场预测

Ulcerative Colitis Market

Market Size

Forecast Period2025-2035

CAGR (2025-2035)4.68%

2025 Market SizeUSD 11.28 Billion

2035 Market SizeUSD 17.82 Billion

Key Players

AbbVie

Johnson & Johnson

Takeda

Pfizer

Bristol-Myers Squibb

Eli Lilly

Trends

Rising Global IBD Incidence
JAK Inhibitor & S1P Class Expansion
Biosimilar-Driven Budget Reallocation

Opportunities

Precision Biomarker-Guided Therapy Selection
Subcutaneous Self-Administration Platforms
Asia-Pacific Market Expansion

摘要目录分割方法论下载PDF

1 引言
1. 1.1 定义
2. 1.2 研究范围
  1. 1.2.1 研究目标
  2. 1.2.2 假设与假设局限性
    1. 1.2.2.1 假设
    2. 1.2.2.2 局限性
3. 1.3 市场结构：
2 研究方法
1. 2.1 研究流程：
2. 2.2 初步研究
3. 2.3 二次研究：
3 市场动态
1. 3.1 驱动因素
2. 3.2 制约因素
3. 3.3 机遇
4. 3.4 宏观经济指标
4 市场因素分析
1. 4.1 波特五力模型
2. 4.2 供应商议价能力
3. 4.3 买方议价能力
4. 4.4 新进入者的威胁
5. 4.5 替代品的威胁
6. 4.6 竞争强度
7. 5全球溃疡性结肠炎市场（按类型划分）
8. 5.1 溃疡性直肠炎
9. 5.2 直肠乙状结肠炎
10. 5.3 左半结肠炎
11. 5.4 全结肠炎或普遍性结肠炎
12. 5.5 暴发性结肠炎
6 全球溃疡性结肠炎市场（按药物划分）
1. 6.1 5-氨基水杨酸盐
2. 6.2 类固醇
3. 6.3 嘌呤类似物
4. 6.4 免疫调节剂
5. 6.5 生物制剂
7 全球溃疡性结肠炎市场（按地区划分）
1. 7.1 北美
  1. 7.1.1 简介
2. 7.2 欧洲
  1. 7.2.1 简介
  2. 7.3.1 简介
3. 7.3亚太地区
4. 7.4 中东和非洲
  1. 7.4.1 简介
8 竞争格局
1. 8.1 市场参与者的主要战略
  1. 8.1.1 战略合作伙伴关系
  2. 8.1.2 并购
9 公司简介
1. 9.1 艾伯维公司
  1. 9.1.1 公司概况
  2. 9.1.2 产品概述
  3. 9.1.3 财务状况
  4. 9.1.4 重要发展
2. 9.2 拜耳股份公司
  1. 9.2.1 概述
  2. 9.2.2 产品概述
  3. 9.2.3 财务状况
  4. 9.2.4 关键发展
3. 9.3 强生强生服务公司
  1. 9.3.1 概述
  2. 9.3.2 产品概述
  3. 9.3.3 财务状况
  4. 9.3.4 战略
  5. 9.3.5 关键发展
4. 9.4 武田制药有限公司
  1. 9.4.1 概述
  2. 9.4.2 产品概述
  3. 9.4.3 财务状况
  4. 9.4.4 关键发展
5. 9.5 辉瑞公司
  1. 9.5.1 概述
  2. 9.5.2 产品概述
  3. 9.5.3 财务状况
  4. 9.5.4 关键发展
6. 9.6 其他
7. 表格列表
8. 表 1：2023-2032 年全球溃疡性结肠炎市场（按类型划分）（美元）十亿美元）
9. 表 2 2023 - 2032 年全球溃疡性结肠炎市场（按药物划分）（十亿美元）
10. 表 3 2023 - 2032 年全球溃疡性结肠炎市场（按地区划分）（十亿美元）
11. 图表目录
12. 图 1 研究流程
13. 图 2 波特五力模型
14. 图 3 全球溃疡性结肠炎市场（按类型划分）
15. 图 4 全球溃疡性结肠炎市场（按药物划分）
16. 图 5 全球溃疡性结肠炎市场（按地区划分）
17. 图 6 全球溃疡性结肠炎市场：公司份额分析

认证研究员

Enquiry

定制报告

溃疡性结肠炎市场细分

溃疡性结肠炎类型展望（十亿美元，2019-2032 年）

溃疡性直肠炎
直肠乙状结肠炎
左侧结肠炎
全结肠炎或普遍性结肠炎
暴发性结肠炎

溃疡性结肠炎药物展望（十亿美元，2019-2032 年）

5-氨基水杨酸盐
类固醇
嘌呤类似物
免疫调节剂
生物制剂

溃疡性结肠炎区域展望（十亿美元，2019-2032）

北美展望（十亿美元，2019-2032）
- 北美溃疡性结肠炎类型
  - 溃疡性直肠炎
  - 直肠乙状结肠炎
  - 左半结肠炎
  - 全结肠炎或普遍性结肠炎
  - 暴发性结肠炎
- 北美溃疡性结肠炎类型药物
  - 5-氨基水杨酸盐
  - 类固醇
  - 嘌呤类似物
  - 免疫调节剂
  - 生物制剂
- 美国展望（十亿美元，2019-2032）
- 美国溃疡性结肠炎类型
  - 溃疡性直肠炎
  - 直肠乙状结肠炎
  - 左侧结肠炎
  - 全结肠炎或普遍性结肠炎
  - 暴发性结肠炎
- 美国溃疡性结肠炎类型药物
  - 5-氨基水杨酸盐
  - 类固醇
  - 嘌呤类似物
  - 免疫调节剂
  - 生物制剂
- 加拿大展望（十亿美元，2019-2032）
- 加拿大溃疡性结肠炎类型
  - 溃疡性直肠炎
  - 直肠乙状结肠炎
  - 左侧结肠炎
  - 全结肠炎或普遍性结肠炎
  - 暴发性结肠炎
- 加拿大溃疡性结肠炎类型药物
  - 5-氨基水杨酸盐
  - 类固醇
  - 嘌呤类似物
  - 免疫调节剂
  - 生物制剂
- 欧洲展望（十亿美元，2019-2032）
  - 欧洲溃疡性结肠炎类型
    - 溃疡性直肠炎
    - 直肠乙状结肠炎
    - 左半结肠炎
    - 全结肠炎或普遍性结肠炎
    - 暴发性结肠炎
  - 欧洲溃疡性结肠炎类型药物
    - 5-氨基水杨酸盐
    - 类固醇
    - 嘌呤类似物
    - 免疫调节剂
    - 生物制剂
  - 德国展望（十亿美元，2019-2032）
  - 德国溃疡性结肠炎类型
    - 溃疡性直肠炎
    - 直肠乙状结肠炎
    - 左侧结肠炎
    - 全结肠炎或普遍性结肠炎
    - 暴发性结肠炎
  - 德国溃疡性结肠炎类型药物
    - 5-氨基水杨酸盐
    - 类固醇
    - 嘌呤类似物
    - 免疫调节剂
    - 生物制剂
  - 法国展望（十亿美元，2019-2032）
  - 法国溃疡性结肠炎类型
    - 溃疡性直肠炎
    - 直肠乙状结肠炎
    - 左半结肠炎
    - 全结肠炎或普遍性结肠炎
    - 暴发性结肠炎
  - 法国溃疡性结肠炎类型药物
    - 5-氨基水杨酸盐
    - 类固醇
    - 嘌呤类似物
    - 免疫调节剂
    - 生物制剂
  - 英国展望（十亿美元，2019-2032）
  - 英国溃疡性结肠炎类型
    - 溃疡性直肠炎
    - 直肠乙状结肠炎
    - 左侧结肠炎
    - 全结肠炎或普遍性结肠炎
    - 暴发性结肠炎
  - 英国溃疡性结肠炎类型
    
    5-氨基水杨酸盐
    
    类固醇
    
    嘌呤类似物
    
    免疫调节剂
    
    生物制剂

Purchase Options

Single User

Multiple License

Enterprise User

认证研究员

Enquiry

Your privacy is our priority. Privacy Policy*

分享

定制报告

相关报告

Ba

Biocatalysts and Enzyme Engineering Market

September 15, 2026

MV

Menopause-Related Vasomotor Symptoms Market

September 15, 2026

WG

Wound Gel Market

September 15, 2026

GM

Gut Microbiome Testing Market

September 15, 2026

II

Intravenous Iron Market

September 15, 2026

该市场没有可用的区域报告。

该市场没有可用的国家报告。

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”
Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”
Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”
La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

案例研究

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Download PDF ×

* Please use a valid business email

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.